TSTickerStarGet alerts

HIMS 10-Q filed 2026-11-09 | Key takeaways

HIMS filed its 10-Q; the most relevant disclosure change is expanded Business combinations: Completed Eucalyptus acquisition in June 2026 for preliminary purchase price of $968.5M (cash of $225M, deferred payments of $683.9M, earn-out up to $96.6M); acquired YourBio Health in January 2026 for $153.0M (cash of $142.4M, earn-out of $10.6M); goodwill in.

Share this story

Key takeaways

  • International revenue surged to $233.3M in Q3 2026 (26% of total) from $55.5M in Q3 2025, driven by Eucalyptus acquisition

  • Restructuring charges of $41.9M recorded YTD related to strategic shift in U.S. weight loss offering to focus on branded GLP-1 and limited compounded GLP-1

  • FTC and state regulators filed complaint in July 2026 alleging violations of FTC Act and ROSCA regarding subscription practices; $60M legal contingency accrual recorded

  • Receivables Purchase Agreement with JPMorgan Chase established for up to $400M; $434.5M in receivables sold YTD for net proceeds of $433.3M

  • 2032 Convertible Notes issued for $402.5M in May 2026; combined with 2030 Convertible Notes, total net carrying value of $1.37B

  • Eucalyptus acquisition closed June 2026 for $968.5M (preliminary) with earn-out potential up to $96.6M; contributed approximately 15% of Q3 revenue

Key metrics

Total RevenueQ3 2026 (three months ended September 30, 2026)
$890.4 million+48.7%
Total RevenueNine months ended September 30, 2026
$2.25 billion+30.2%
Operating (Loss) IncomeQ3 2026
($66.1 million)N/A - turned to loss from $11.8M income
Net (Loss) IncomeQ3 2026
($33.0 million)N/A - turned to loss from $15.8M income
Net (Loss) IncomeNine months ended September 30, 2026
($211.4 million)N/A - turned to loss from $107.8M income
Basic EPSQ3 2026
($0.14)N/A - from $0.07
Diluted EPSQ3 2026
($0.14)N/A - from $0.06
Basic EPSNine months ended September 30, 2026
($0.91)N/A - from $0.48

Disclosure changes

  • Business combinations

    Completed Eucalyptus acquisition in June 2026 for preliminary purchase price of $968.5M (cash of $225M, deferred payments of $683.9M, earn-out up to $96.6M); acquired YourBio Health in January 2026 for $153.0M (cash of $142.4M, earn-out of $10.6M); goodwill increased from $278.3M to $1.11B

    Significant acquisition activity has materially changed the company's scale, international footprint, and cost structure
  • Legal proceedings

    FTC and state regulators (Utah, California) filed complaint in July 2026 alleging violations of FTC Act and ROSCA regarding privacy, advertising, subscription, and cancellation practices; $60M legal contingency accrual recorded; motion to dismiss filed October 2026; putative class action filed based on same underlying facts

    Material legal contingency with potential for permanent injunction, monetary relief, civil penalties, and business operational changes
  • Restructuring charges

    In March 2026, announced strategic shift for U.S. weight loss offering to match global approach; recorded $3.8M in Q3 2026 and $41.9M YTD in restructuring and other related charges ($28.5M in cost of revenue, $13.4M in operating expenses)

    Strategic pivot in weight loss business may impact future revenue trajectory and profitability
  • Receivables and receivables purchase facility

    Receivables, net increased to $427.8M from $32.1M; includes manufacturer's discount and rebate receivables of $345.3M and loss recovery receivables of $26.0M; RPA with JPMorgan Chase provides up to $400M facility; sold $434.5M receivables YTD for net proceeds of $433.3M

    Significant growth in receivables reflects new vendor rebate arrangements and receivables securitization provides liquidity
  • Revenue disaggregation

    International revenue grew to $233.3M (26% of total) in Q3 2026 from $55.5M in Q3 2025; U.S. revenue grew to $657.1M from $543.5M

    International operations now represent significant portion of revenue following Eucalyptus acquisition
  • Convertible notes

    2032 Convertible Notes of $402.5M issued May 2026 (net proceeds $389.5M, conversion price $29.53, convertible into 33.8590 shares per $1,000); combined net carrying value of $1.37B for both note series

    Additional debt financing increases leverage and future dilution risk

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow HIMS in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert